Orsini, a provider of rare disease pharmacy solutions, has launched an integrated specialty pharmacy and third-party logistics (3PL) solution, supported by the company’s new Columbus, Ohio facility. The launch expands Orsini’s nationwide capabilities and strengthens its ability to deliver end-to-end support for biopharma partners launching rare disease therapies.

The Columbus facility, now fully operational and licensed to dispense medication in all 50 states, strengthens Orsini’s infrastructure with comprehensive specialty pharmacy redundancy, co-located 3PL capabilities, and advanced ultra-cold storage to support gene and cell therapy programs. By combining specialty pharmacy and 3PL services under one roof, Orsini delivers an integrated model designed specifically for rare disease therapies where Orsini serves as the exclusive specialty pharmacy partner.

“This launch represents more than an expansion — it’s an investment in our mission to improve the lives of patients and families affected by rare diseases,” said Brandon Tom, Orsini’s CEO. “The Columbus facility strengthens our operational platform and enhances our ability to deliver a seamless experience for both patients and partners.”